Larimar to trade down on delayed FDA submission, says JonesResearch

JonesResearch says Larimar Therapeutics (LRMR) announced the application submission for nomlabofusp in Friedreich’s Ataxia is targeted for Q2 of 2026, which is pushed back from year-end 2025 based on FDA feedback on safety database requirements. The firm expects the stock could trade down initially given the delay, but still sees the news “as a step in the right direction.” Larimar’s biggest overhang was regulatory uncertainty, specifically with regard to accelerated approval, the analyst tells investors in a research note. Having written recommendations from the FDA should alleviate some of these concerns, contends JonesResearch. It keeps a Buy rating on the shares with a $14 price target The stock in premarket trading is down 6% to $2.43.